摘要
目的研究18F-脱氧葡萄糖(18F-fluorodeoxyglucose,18F-FDG)SPECT/CT符合线路显像在非小细胞肺癌放疗中的临床应用价值。方法 17例非小细胞肺癌患者,放疗前后行18F-FDG SPECT/CT符合线路显像,必要时放疗靶区根据治疗前18F-FDG SPECT/CT符合线路显像结果进行修正,全部患者均随访12个月并根据临床及影像学随访评价为局部控制或失败,分析肿瘤区域18F-FDG摄取情况的变化及其与疗效的关系。结果 64.7%(11/17)的患者放疗靶区需根据18F-FDG SPECT/CT符合线路显像结果进行修正,全部患者1年局部控制率为70.6%(12/17),放疗后肿瘤区域18F-FDG摄取明显低于放疗前(P<0.01)。结论18F-FDG SPECT/CT符合线路显像可用于非小细胞肺癌放疗靶区的确定、放疗后疗效的预测与随访,且较为经济、简便。
Objective： To evaluate the clinical application value of 18F-FDG SPECT / CT coincidence imaging in patients with non-small cell lung cancer before and after radiotherapy.Methods： In 17 patients with non-small cell lung cancer,18F-FDG SPECT / CT coincidence imaging was performed before and after radiotherapy.If necessary,the target volume delineation was modified according to the 18F-FDG SPECT / CT coincidence imaging before radiotherapy.All of the patients were followed clinically and radiographically in 12 months for assessment of local control or failure.The correlation between the uptake of 18F-FDG in malignant regions and prognosis was analyzed.Results： In 11 patients（64.7%）,the target volume delineation was modified.One year local control rate of all patients was 70.6%（12 /17）.There was a significant reduction in the uptake of 18F-FDG in malignant regions after radiotherapy（P 0.01）.Conclusion： As a more economical methods,the 18F-FDG SPECT / CT coincidence imaging can be used in the target volume delineation before radiotherapy in patients with non-small cell lung cancer,predicting their therapy response and following up.
出处
《泰山医学院学报》
CAS
2013年第4期252-254,共3页
Journal of Taishan Medical College
